Recently, it has been described that HAS2 antisense 1 (HAS2–AS1), a long-noncoding RNA that belongs to the class of natural antisense transcripts, is able to control HAS2 epigenetically (32) and that HAS2–AS1 is able to alter the chromatin structure around the HAS2 promoter inducing HAS2 transcription in vascular smooth muscle cells (33) and tumor cells (34, 35). This evidence concerns the gene HAS2 and neoplasm.